PDOX Bibliography with Comments

A selection of published PDOX studies. These studies are available by request.

Search Bibliography :

  1. Fu, X., Besterman, J.M., Monosov, A., and Hoffman, R.M. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc. Natl. Acad. Sci. USA 88, 9345-9349, 1991.
  2. The first PDOX model and the first paper to show metastasis of a human patient tumor. PDOX showed patient-like metastasis of a colon carcinoma.

  3. Fu, X., Guadagni, F., and Hoffman, R.M. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically from histologically intact patient specimens. Proc. Natl. Acad. Sci. USA 89, 5645-5649, 1992.
  4. The first PDOX model of pancreatic cancer. PDOX showed patient-like metastasis.

  5. Wang, X., Fu, X., and Hoffman, R.M. A new patient-like metastatic model of human lung cancer constructed orthotopically with intact tissue via thoracotomy in immunodeficient mice. Int. J. Cancer 51, 992-995, 1992.
  6. The first PDOX model of lung cancer. PDOX showed patient-like metastasis.

  7. Fu, X., and Hoffman, R.M. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res. 13, 283-286, 1993.
  8. The first PDOX model of ovarian cancer. PDOX showed patient-like metastasis.

  9. Fu, X., Le, P. and Hoffman, R.M. A metastatic-orthotopic transplant nude-mouse model of human patient breast cancer. Anticancer Res. 13, 901-904, 1993.
  10. The first PDOX model of breast cancer. PDOX showed patient-like metastasis.

  11. Furukawa, T., Kubota, T., Watanabe, M., Kitajima, M., Fu, X. and Hoffman, R.M. Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice: correlation of metastatic sites in mouse and individual patient donors. Int. J. Cancer 53, 608-612, 1993.
  12. The first patient-like model of stomach cancer. PDOX metastasis correlated with patient metastasis in a series of 20 patients.

  13. Astoul, P., Colt, H.G., Wang, X., and Hoffman, R.M. Metastatic human pleural ovarian cancer model constructed by orthotopic implantation of fresh histologically-intact patient carcinoma in nude mice. Anticancer Res. 13, 1999-2002, 1993.
  14. The first PDOX model of pleural metastasis of ovarian cancer.

  15. Astoul, P., Wang, X., and Hoffman, R.M. "Patient-like" nude- and SCID-mouse models of human lung and pleural cancer (Review). Int. J. Oncology 3, 713-718, 1993.
  16. A review of PDOX models of lung and pleural cancer.

  17. Astoul, P., Colt, H.G., Wang, X., and Hoffman, R.M. A “patient-like” nude mouse model of parietal pleural human lung adenocarcinoma. Anticancer Res. 14, 85-91, 1994.
  18. The first PDOX model of parietal pleural lung cancer metastasis.

  19. Astoul, P., Colt, H.G., Wang, X., Boutin, C. and Hoffman, R.M. “Patient-like” nude mouse metastatic model of advanced human pleural cancer. Journal of Cellular Biochemistry 56, 9-15, 1994.
  20. A review of PDOX models of pleural metastasis.

  21. Togo, S., Wang, X., Shimada, H., Moossa, A.R., and Hoffman, R.M. Cancer seed and soil can be highly selective: Human-patient colon tumor lung metastasis grows in nude mouse lung but not colon or subcutis. Anticancer Res. 15, 795-798, 1995.
  22. A PDOX model of lung metastasis of colon cancer.

  23. Astoul, P., Wang, X., Colt, H.G., Boutin, C., and Hoffman, R.M. A patient-like human malignant pleural mesothelioma nude-mouse model. Oncology Reports 3, 483-487, 1996.
  24. The first PDOX model of mesothelioma.

  25. Riordan, T. A technique is said to ease attachment of tumors to mice, making them ‘little cancer patients.’ New York Times, “Patents” Column, March 4, 1996.
  26. PDOX recognized by the New York Times.

  27. Holzman, D. Of mice and metastasis: A new for-profit model emerges. J. Natl. Cancer Inst. 88, 396-397, 1996.
  28. Commentary from NCI on the PDOX model.

  29. Hoffman, R.M. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Investigational New Drugs 17, 343-359, 1999.
  30. Review of PDOX models.

  31. Garber, K. Realistic rodents? Debate grows over new mouse models of cancer. J. Natl. Cancer Inst. 98, 1176-1178, 2006.
  32. Review of mouse models.

  33. Lukashev, M., LePage, D., Wilson, C., Bailly, V., Garber, E., Lukashin, A., Ngam-ek, A., Zeng, W., Allaire, N., Perrin, S., Xu, X., Szeliga, K., Wortham, K., Kelly, R., Bottiglio, C., Ding, J., Griffith, L., Heaney, G., Silverio, E., Yang, W., Jarpe, M., Fawell, S., Reff, M., Carmillo, A., Miatkowski, K., Amatucci, J., Crowell, T., Prentice, H., Meier, W., Violette, S.M., Mackay, F., Yang, D., Hoffman, R., and Browning, J.L. Targeting the lymphotoxin-b receptor with agonist antibodies as a potential cancer therapy. Cancer Research 66, 9617-9624, 2006.
  34. Use of PDOX models for immunotherapy.

  35. Kaushal, S., McElroy, M.K., Luiken, G.A., Talamini, M.A., Moossa, A.R., Hoffman, R.M., and Bouvet, M. Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer. J. Gastrointest. Surg. 12, 1938-1950, 2008.
  36. Use of PDOX models for fluorescent-guided surgery.

  37. Soda, Y., Marumoto, T., Friedmann-Morvinski, D., Soda, M., Liu, F., Michiue, H., Pastorino, S., Yang, M., Hoffman, R.M., Kesari, S., Verma, I.M. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl. Acad. Sci. USA 108, 4274-4280, 2011.
  38. First PDOX model of glioma.

  39. Suetsugu, A., Katz, M., Fleming, J., Moriwaki, H., Bouvet, M., Saji, S., and Hoffman, R.M. Multi-color palette of fluorescent proteins for imaging the tumor microenvironment of orthotopic tumorgraft mouse models of clinical pancreatic cancer specimens. J. Cell. Biochem. 113, 2290-2295, 2012.
  40. First imageable PDOX model (also known as iPDOX).

  41. Suetsugu, A., Katz, M., Fleming, J., Truty, M., Thomas, R., Saji, S., Moriwaki, H., Bouvet, M., and Hoffman, R.M. Imageable fluorescent metastasis resulting in transgenic GFP mice orthotopically implanted with human-patient primary pancreatic cancer specimens. Anticancer Research 32, 1175-1180, 2012.
  42. iPDOX model used to image tumor stroma at cellular level.

  43. Suetsugu, A., Katz, M., Fleming, J., Truty, M., Thomas, R., Saji, S., Moriwaki, H., Bouvet, M., and Hoffman, R.M. Non-invasive fluorescent-protein imaging of orthotopic pancreatic-cancer-patient tumorgraft progression in nude mice. Anticancer Research 32, 3063-3067, 2012.
  44. iPDOX model imaged noninvasively.

  45. Hiroshima, Y., Maawy, A., Sato, S., Murakami, T., Uehara, F., Miwa, S., Yano., S., Momiyama, M., Chishima, T., Tanaka, K., Bouvet, M., Endo, I., and Hoffman, R.M. Hand-held high-resolution fluorescence imaging system for fluorescence-guided surgery of patient and cell-line pancreatic tumors growing orthotopically in nude mice. J. Surg. Res. 187, 510-517, 2014.
  46. PDOX model for development of successful fluorescence-guided surgery.

  47. Metildi, C.A., Kaushal, S., Luiken, G.A., Talamini, M.A., Hoffman, R.M., and Bouvet, M. Fluorescently-labeled chimeric anti-CEA antibody improves detection and resection of human colon cancer in a patient-derived orthotopic xenograft (PDOX) nude mouse model. J Surg. Oncol. 109, 451-458, 2014.
  48. PDOX model to develop curative fluorescence-guided surgery of colon cancer.

  49. Hiroshima, Y., Maawy, A., Metildi, C.A.., Zhang, Y., Uehara, F., Miwa, S., Yano, S., Sato, S., Murakami, T., Momiyama, M., Chishima, T., Tanaka, K., Bouvet, M., Endo, I., and Hoffman, R.M. Successful fluorescence-guided surgery on human colon cancer patient-derived orthotopic xenograft mouse models using a fluorophore-conjugated anti-CEA antibody and a portable imaging system. J. Laparoendosc. Adv. Surg. Tech. A 24, 241-247, 2014.
  50. PDOX model used to develop fluorescence-guided surgery with labeled antibodies.

  51. Hiroshima, Y., Zhao, M., Maawy, A., Zhang, Y., Katz, M.H., Fleming, J.B., Uehara, F., Miwa, S., Yano, S., Momiyama, M., Suetsugu, A., Chishima, T., Tanaka, K., Bouvet, M., Endo, I., and Hoffman, R.M. Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX). J. Cell. Biochem. 115, 1254-1261, 2014.
  52. PDOX model to develop bacterial therapy of pancreatic cancer.

  53. Hiroshima, Y., Maawy, A., Zhang, Y., Murakami, T., Momiyama, M., Mori, R., Matsuyama, R., Katz, M.H., Fleming, J.B., Chishima, T., Tanaka, K., Ichikawa, Y., Endo, I., Hoffman, R.M., and Bouvet, M. Metastatic recurrence in a pancreatic cancer patient derived orthotopic xenograft (PDOX) nude mouse model is inhibited by neoadjuvant chemotherapy in combination with fluorescence-guided surgery with an anti-CA 19-9-conjugated fluorophore. PLoS One 9, e114310, 2014.
  54. PDOX model used to combine fluorescence-guided surgery with chemotherapy of pancreatic cancer.

  55. Hiroshima, Y., Zhang, Y., Murakami, T., Maawy, A.A., Miwa, S., Yamamoto, M., Yano, S., Sato, S., Momiyama, M., Mori, R., Matsuyama, R., Chishima, T., Tanaka, K., Ichikawa, Y., Bouvet, M., Endo, I., Zhao, M., and Hoffman, R.M. Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograph (PDOX) and cell line mouse models. Oncotarget 5, 12346-12357, 2014.
  56. PDOX model used to develop combined bacterial and anti-angiogenesis therapy of cancer.

  57. Hiroshima, Y., Zhang, Y., Zhang, M., Maawy, A., Mii, S., Yamamoto, M., Uehara, F., Miwa, S., Yano, S., Murakami, T., Momiyama, M., Chishima, T., Tanaka, K., Ichikawa, Y., Bouvet, M., Murata, T., Endo, I., and Hoffman, R.M. Establishment of a patient-derived orthotopic xenograph (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. PLOS ONE 10, e0117417, 2015.
  58. The first PDOX model of cervical cancer. PDOX and patient had similar metastasis.

  59. Hiroshima, Y., Zhang, Y., Zhang, N., Uehara, F., Maawy, A., Murakami, T., Mii, S., Yamamoto, M., Miwa, S., Yano, S., Momiyama, M., Mori, R., Matsuyama, R., Chishima, T., Tanaka, K., Ichikawa, Y., Bouvet, M., Endo, I., and Hoffman, R.M. Patient-derived orthotopic xenograft (PDOX) nude mouse model of soft-tissue sarcoma more closely mimics the patient behavior in contrast to the subcutaneous ectopic model. Anticancer Research 35, 697-701, 2015.
  60. The first PDOX model of soft tissue sarcoma.

  61. Hiroshima, Y., Maawy, A.A., Katz, M.H., Fleming, J.B., Bouvet, M., Endo, I., and Hoffman, R.M. Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer. J. Surg. Oncol. 111, 311-315, 2015.
  62. The first PDOX model to develop anti-metastasis therapy.

  63. Hiroshima, Y., Maawy, A.A., Katz, M.H., Fleming, J.B., Bouvet, M., Endo, I., and Hoffman, R.M. Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer. J. Surg. Oncol. 111, 311-315, 2015.
  64. PDOX efficacy for pancreatic metastasis.

  65. Hiroshima, Y., Maawy, A., Zhan, Y., Murakami, T., Momiyama, M., Mori, R., Matsuyama, R., Chishima, T., Tanaka, K., Ichikawa, Y., Endo, I., Hoffman, R.M., and Bouvet, M. Fluorescence-guided surgery, but not bright-light surgery, prevents local recurrence in a pancreatic cancer patient-derived orthotopic xenograft (PDOX) model resistant to neoadjuvant chemotherapy (NAC). Pancreatology 15, 295-301, 2015.
  66. PDOX model to develop fluorescence-guided surgery of chemoresistant pancreatic cancer.

  67. Hoffman, R.M. Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nature Reviews Cancer 15, 451-452, 2015.
  68. A review of PDOX in world’s foremost cancer journal.

  69. Yano, S., Hiroshima, Y., Maawy, A., Kishimoto, H., Suetsugu, A., Miwa, S., Toneri, M., Yamamoto, M., Katz, M.H.G., Fleming, J.B., Urata, Y., Tazawa, H., Kagawa, S., Bouvet, M., Fujiwara, T., and Hoffman, R.M. Color-coding cancer and stromal cells with genetic reporters in a patient-derived orthotopic xenograft (PDOX) model of pancreatic cancer enhances fluorescence-guided surgery. Cancer Gene Therapy 22, 344-350, 2015.
  70. Color-coded iPDOX model, labeling cancer cells and stromal cells, for fluorescence-guided surgery.

  71. Hiroshima, Y., Zhao, M., Zhang, Y., Zhang, N., Maawy, A., Murakami, T., Mii, S., Uehara, F., Yamamoto, M., Miwa, S., Yano, S., Momiyama, M., Mori, R., Matsuyama, R., Chishima, T., Tanaka, K., Ichikawa, Y., Bouvet, M., Endo, I., and Hoffman, R.M. Tumor-targeting Salmonella typhimurium A1-R arrests a chemo-resistant patient soft-tissue sarcoma in nude mice. PLoS One 10, e0134324, 2015.
  72. PDX model shows efficacy of bacterial therapy of sarcoma.

  73. Murakami, T., DeLong, J., Eilber, F.C., Zhao, M., Zhang, Y., Zhang, N., Singh, A., Russell, T., Deng, S., Reynoso, J., Quan, C., Hiroshima, Y., Matsuyama, R., Chishima, T., Tanaka, K., Bouvet, M., Chawla, S., Endo, I., and Hoffman, R.M. Tumor-targeting Salmonella typhimurium A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft PDOX model. Oncotarget 7, 12783-12790, 2016.
  74. The first PDOX model to correlate doxorubicin resistance in patients and PDOX in soft-tissue sarcoma.

  75. Kiyuna, T., Murakami, T., Tome, Y., Kawaguchi, K., Igarashi, K., Zhang, Y, Zhao, M., Li, Y., Bouvet, M., Kanaya, F., Singh, A., Dry, S., Eilber, F.C., and Hoffman, R.M. High efficacy of tumor-targeting Salmonella typhimurium A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model. Oncotarget 7, 33046-33054, 2016.
  76. The first PDOX model of follicular dendritic-cell sarcoma, also shows efficacy of bacterial efficacy.

  77. Jun, E., Jung, J., Jeong, S-Y., Choi, E.K., Kim, M. B., Lee, J. S., Hong, S-M., Seol, H. S., Hwang, C., Hoffman, R.M., Shim, I. K., Chang, S., and Kim, S. C. Surgical and oncological factors affecting the successful engraftment of patient-derived xenografts in pancreatic ductal adenocarcinoma. Anticancer Res. 36, 517-522, 2016.
  78. Factors for successful PDOX in pancreatic ductal adenocarcinoma.

  79. Hoffman, R.M., and Bouvet, M. Imaging the microenvironment of pancreatic cancer patient-derived orthotopic xenografts (PDOX) growing in transgenic nude mice expressing GFP, RFP, or CFP. Cancer Letters (Special Issue: Tumor Microenvironment. Singh, Shree Ram, ed.), 380, 349-355, 2016.
  80. A review of iPDOX imaging.

  81. Yamamoto, M., Zhao, M., Hiroshima, Y., Zhang, Y., Shurell, E., Eilber, F.C., Bouvet, M., Noda, M.,Hoffman, R.M. Efficacy of tumor-targeting Salmonella typhimurium A1-R on a melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. PLoS One 11, e0160882, 2016.
  82. The first PDOX model of melanoma.

  83. Murakami, T., Singh, A.S., Kiyuna, T., Dry, S.M., Li, Y., James, A.W., Igarashi, K., Kawaguchi, K., DeLong, J.C., Zhang, Y., Hiroshima, Y., Russell, T., Eckardt, M.A., Yanagawa, J., Federman, N., Matsuyama, R., Chishima, T., Tanaka, K., Bouvet, M., Endo, I., Eilber, F.C., and Hoffman, R.M. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget 7, 47556-47564, 2016.
  84. The first PDOX model to demonstrate molecular targeting of Ewing’s sarcoma.

  85. Hiroshima, Y., Maawy, A., Zhang, Y., Zhang, N., Murakami, T., Chishima, T., Tanaka, K.., Ichikawa, Y., Bouvet, M., Endo, I., Hoffman, R.M. Patient-derived mouse models of cancer need to be orthotopic in order to evaluate targeted anti-metastatic therapy. Oncotarget 7, 71696-71702, 2016.
  86. A demonstration of differential chemo-sensitivity of primary and metastasis in PDOX.

  87. Kawaguchi, K., Murakami, T., Chmielowski, B., Igarashi, K., Kiyuna, T., Unno, M., Nelson, S.D., Russell, T.A., Dry, S.M., Li, Y., Eilber, F.C., and Hoffman, R.M. Vemurafenib-resistant BRAF-V600E mutated melanoma is regressed by MEK targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. Oncotarget 7, 71737-71743, 2016.
  88. Demonstrates PDOX is necessary to choose effective molecular targeting drugs for melanoma.

  89. Kawaguchi, K., Igarashi, K., Murakami, T., Chmiewloski, B., Kiyuna, T., Zhao, M., Zhang, Y., Singh, A., Unno, M., Nelson, S.D., Russell, T., Dry, S.M., Li, Y., Eilber, F.C., Hoffman, R.M. Tumor-targeting Salmonella typhimurium A1-R combined with Temozolomide regresses malignant melanoma with a BRAF-V600 mutation in a patient-derived orthotopic xenograft (PDOX) model. Oncotarget 7, 85929-85936, 2016.
  90. PDOX models demonstrates that bacterial therapy sensitizes melanoma to first line therapy.

  91. Hoover, M., Adamian, Y., Brown, M., Maawy, A., Chang, A., Lee, J., Gharibi, A., Katz, M.H., Fleming, J., Hoffman, R.M., Bouvet, M., Doebler, R., and Kelber J.A. A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts. Oncotarget 8, 5885-5894, 2017.
  92. Shows differential gene expression in PDX and PDOX models.

  93. Murakami, T., Murata, T., Kawaguchi, K., Kiyuna, T., Igarashi, K., Hwang, H.K., Hiroshima, Y., Hozumi, C., Komatsu, S., Kikuchi, T., Lwin, T.M., Delong, J.C., Miyake, K., Zhang, Y., Tanaka, K., Bouvet, M., Endo, I., Hoffman, R.M. Cervical cancer patient-derived orthotopic xenograft (PDOX) is sensitive to cisplatinum and resistant to nab-paclitaxel. Anticancer Research 37, 61-65, 2017.
  94. The PDOX model identifies effective therapy of cervical cancer.

  95. Kiyuna, T., Murakami, T., Tome, Y., Igarashi, K., Kawaguchi, K., Russell, T., Eckhardt, M.A., Crompton, J., Singh, A., Bernthal, N., Bukata, S., Federman, N., Kanaya, F., Eilber, F.C., and Hoffman, R.M. Labeling the stroma of a patient-derived orthotopic xenograft (PDOX) mouse models of undifferentiated pleomorphic soft-tissue sarcoma with red fluorescent protein for rapid non-invasive drug screening. J. Cell. Biochem. 118, 361-365, 2017.
  96. The first demonstration of one-passage labeling of PDOX with red fluorescent protein.

  97. Murakami, T., Igarashi, K., Kawaguchi, K., Kiyuna, T., Zhang, Y., Zhao, M., Hiroshima, Y., Nelson, S.D., Dry, S.M., Li, Y., Yanagawa, J., Russell, T., Federman, N., Singh, A., Elliott, I., Matsuyama, R., Chishima, T., Tanaka, K., Endo, I., Eilber, F.C., and Hoffman, R.M. Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograph model resistant to a molecular-targeting drug. Oncotarget 8, 8035-8042, 2017.
  98. The first PDOX paper to show Salmonella typhimurium A1-R can regress a patient osteosarcoma resistant to a molecular targeting drug.

  99. Igarashi, K., Kawaguchi, K., Kiyuna, T., Murakami, T., Miwa, S., Nelson, S.D., Dry, S.M., Li, Y., Singh, A., Kimura, H., Hayashi, K., Yamamoto, N., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. Patient-derived orthotopic xenograft (PDOX) mouse model of adult rhabdomyosarcoma invades and recurs after resection in contrast to the subcutaneous ectopic model. Cell Cycle 16, 91-94, 2017.
  100. The first PDOX paper to show that the orthotopic sarcoma model is aggressive and the subcutaneous model is benign.

  101. Bouvet, M., Hoffman, R.M. Curative fluorescence guided surgery of gastrointestinal cancers developed in patient derived orthotopic xenograft mouse models. J. Fluores Guided Surg. 1, 5-16, 2017.
  102. The first review of the use of PDOX models for the development of fluorescence-guided surgery.

  103. Kawaguchi, K., Igarashi, K., Chmielowski, B., Murakami, T., Kiyuna, T., Zhao, M., Zhang, Y., Nelson, S.D., Russell, T.A., Dry, S.M., Singh, A.S., Li, Y., Unno, M., Eilber, F.C., and Hoffman, R.M. Salmonella typhimurium A1-R targeting of a chemotherapy resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib-temozlomide. Cell Cycle, in press.
  104. Tumor-targeting Salmonella typhimurium A1-R enhances melanoma chemotherapy resistance in a PDOX model.

  105. Kawaguchi, K., Igarashi, K., Murakami, T., Zhao, M., Zhang, Y., Chmielowski, B., Kiyuna, T., Nelson, S.D., Russell, T.A., Dry, S.M., Li, Y., Unno, M., Eilber, F.C., and Hoffman, R.M. Tumor-targeting Salmonella typhimurium A1-R sensitizes melanoma with a BRAF-V600E mutation to vemurafenib in a patient-derived orthotopic xenograft (PDOX) nude mouse model. J. Cell. Biochem., Epub ahead of print. DOI: 10.1002/jcb.25886.
  106. Tumor-targeting Salmonella typhimurium A1-R sensitizes a melanoma PDOX to a molecular targeting drug.

  107. Murakami, T., Kiyuna, T., Kawaguchi, K., Igarashi, K., Singh A.S., Hiroshima, Y., Zhang Y., Zhao, M., Miyake, K., Nelson S.D., Dry, S.M., Li, Y., DeLong, J.C., Lwin, T.M., Chishima, T., Tanaka, K., Bouvet, M., Endo, I., Eilber, F.C., Hoffman, R.M. The irony of highly-effective bacterial therapy of a patient-derived mouse model of Ewing’s sarcoma, which was blocked by Ewing himself 80 years ago. Cell Cycle, in press.
  108. Salmonella typhimurium A1-R bacterial therapy is active against a Ewing’s sarcoma PDOX.

  109. Murakami, T., Li, S., Han, Q., Tan, Y., Kiyuna, T., Igarashi, K., Kawaguchi, K., Hwang, H.K., Miyaki, K., Singh, A.S., Nelson, S.D., Dry, S.M., Li, Y., Hiroshima, Y., Lwin, T.M., DeLong, J.C., Chishima, T., Tanaka, K.., Bouvet, M., Endo, I., Eilber, F.C., and Hoffman, R.M. Recombinant methioninase effectively targets a Ewing’s sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget 8, 35630-35638, 2017.
  110. PDOX efficacy for Ewing’s sarcoma.

  111. Kawaguchi, K., Igarashi, K., Murakami, T., Kiyuna, T., Nelson, S.D., Dry, S.M., Li, Y., Russell, T.A., Singh, A.S., Chmielowski, B., Unno, M., Eilber, F.C., and Hoffman, R.M. Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. Cell Cycle 16, 1063-1069, 2017.
  112. Efficacy of imageable PDOX model.

  113. Igarashi, K., Kawaguchi, K., Murakami, T., Kiyuna, T., Miyake, K., Nelson, S.D., Dry, S.M., Li, Y., Yanagawa, J., Russell, T.A., Singh, A., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. Cell Cycle, in press.
  114. Intra-arterial chemotherapy regresses a cisplatinum-resistant osteosarcoma PDOX.

  115. Igarashi, K., Kawaguchi, K., Murakami, T., Kiyuna, T., Miyake, K., Singh, A., Nelson, S.D., Dry, S.M., Li, Y., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. High efficacy of pazopanib on an undifferentiated spindle-cell sarcoma resistant to first-line therapy is identified with a patient-derived orthotopic xenograft (PDOX) nude mouse model. J. Cell. Biochem., Epub ahead of print. DOI: 10.1002/jcb.25923
  116. PDOX efficacy for spindle-cell sarcoma.

  117. Kiyuna, T., Murakami, T., Tome, Y., Kawaguchi, K., Igarashi, K., Miyake, K., Kanaya, F., Singh, A., Eilber, F.C., and Hoffman, R.M. Analysis of stroma labeling during multiple passage of a sarcoma imageable patient-derived orthotopic xenograft (iPDOX) in red fluorescent protein transgenic nude mice. J Cell. Biochem., Epub ahead of print. DOI: 10.1002/jcb.25991.
  118. Stroma labeling with a red imageable PDOX model.

  119. Igarashi, K., Kawaguchi, K., Kiyuna, T., Murakami, T., Miwa, S., Nelson, S.D., Dry, S.M., Li, Y., Singh, A., Kimura, H., Hayashi, K., Yamamoto, N., Tsuchiya, H., Eilber, F.C., Hoffman, R.M. Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. Oncotarget, Epub ahead of print. DOI: 10.18632/oncotrget.16548.
  120. PDOX efficacy for rhabdomyosarcoma.

  121. Kawaguchi, K., Igarashi, K., Murakami, T., Kiyuna, T., Lwin, T., Hwang, H-K., DeLong, J., Clary, B., Bouvet, M., Unno, M., and Hoffman, R.M. MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX). Oncotarget, Epub ahead of print. DOI: 10.18632/Oncotarget.17667.
  122. PDOX efficacy for pancreatic cancer.

  123. Kawaguchi, K., Igarashi, K., Chmielowski, B., Murakami, T., Kiyuna, T., Zhao, M., Zhang, Y., Nelson, S.D., Russell, T.A., Dry, S.M., Singh, A.S., Li, Y., Unno, M., Eilber, F.C., and Hoffman, R.M. Salmonella typhimurium A1-R targeting of a chemotherapy resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozlomide. Cell Cycle, Epub ahead of print. DOI: 10.1080/15384101.2017.1314420.
  124. PDOX efficacy for melanoma.

  125. Igarashi, K., Murakami, T., Kawaguchi, K., Kiyuna, T., Miyake, K., Zhang, Y., Nelson, S.D., Dry, S.M., Li, Y., Yanagawa, J., Russell, T.A., Singh, A., Tsuchiya, H., Eilber, F.C., and Hoffman, R.M. A patient-derived orthotopic xenograft (PDOX) mouse model of an cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. Oncotarget, in press.
  126. PDOX efficacy for lung metastasis.

  127. Kawaguchi, K., Igarashi, K., Murakami, T., Kiyuna, T., Lwin, T., Hwang, H-K., DeLong, J., Clary, B., Bouvet, M., Unno, M., and Hoffman, R.M. MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX). Oncotarget, Epub ahead of print.
  128. PDOX efficacy for pancreatic cancer.

  129. Russell, T.A., Eckardt, M., Murakami, T., Eilliot, I., Kawaguchi, K., Kiyuna, T., Igarashi, K., Li, Y., Crompton, J., Graham, D.S., Dry, S.M., Bernthal, N., Yanagawa, J., Kalbasi, A., Federman, M., Chmielowski, B., Singh, A., Hoffman, R.M., Eilber, F.C. Clinical factors impacting the establishment of soft tissue sarcoma patient-derived orthotopic xenograft (PDOX): A UCLA sarcoma program prospective clinical trial. JCO Precision Oncology, in press.
  130. PDOX efficacy for soft tissue sarcoma in UCLA prospective clinical trial.

  131. Kawaguchi, K., Igarashi, K., Li, S., Han, Q., Tan, Y., Kiyuna, T., Miyake, Y., Murakami, T., Chmielowski, B., Nelson, S.D., Russell, T.A., Dry, S.M., Li, Y., Unno, M., Eilber, F.C., and Hoffman, R.M. Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma growth in a patient-derived orthotopic xenograft. Oncotarget, in press.
  132. PDOX efficacy for melanoma.

  133. Miyake, K., Murakami, T., Kiyuna, T., Igarashi, K., Kawaguchi, K., Li, Y., Singh, A.S., Dry, S.M., Eckardt, M.A., Hiroshima, Y., Momiyama, M., Matsuyama, R., Chishima, T., Endo, I., Eilber, F.C., Hoffman, R.M. Eribulin regresses a doxorubicin-resistant Ewing’s sarcoma with a FUS-ERG fusion and CDKN2A-deletion for the patient-derived orthotopic xenograft (PDOX) nude mouse model. J. Cell. Biochem., in press.
  134. PDOX efficacy for Ewing’s sarcoma.